These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 22145227)

  • 21. Surveillance of iclaprim activity: in vitro susceptibility of Gram-positive skin infection pathogens collected from 2015 to 2016 from North America and Europe.
    Huang DB; Magnet S; De Angelis S; Holland TL; File TM; Dryden M; Corey GR; Torres A; Wilcox MH
    Diagn Microbiol Infect Dis; 2019 Feb; 93(2):154-158. PubMed ID: 30266399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antibiotic therapy by suppurative diseases of the abdominal cavity and soft tissues].
    Sazhin VP; Bodrova NG; Klimov DE; Iurishchev VA; Avdovenko AL; Sazhin IV
    Khirurgiia (Mosk); 2010; (6):4-9. PubMed ID: 20559216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002.
    Bouchillon SK; Hoban DJ; Johnson BM; Stevens TM; Dowzicky MJ; Wu DH; Bradford PA
    Diagn Microbiol Infect Dis; 2005 Apr; 51(4):291-5. PubMed ID: 15808321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011).
    Pfaller MA; Flamm RK; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2014 Apr; 78(4):422-8. PubMed ID: 24445158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies.
    Krause KM; Barriere SL; Kitt MM; Benton BM
    Diagn Microbiol Infect Dis; 2010 Oct; 68(2):181-5. PubMed ID: 20846593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections.
    Pfaller MA; Rhomberg PR; Sader HS; Mendes RE; Jones RN
    J Chemother; 2010 Oct; 22(5):304-11. PubMed ID: 21123152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Empirical antibiotic therapy of complicated skin and soft tissue infections in dermatological practice].
    Magyar A; Garaczi E; Hajdú E; Kemény L
    Orv Hetil; 2011 Feb; 152(7):252-8. PubMed ID: 21296734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increasing incidence of Gram-negative organisms in bacterial agents isolated from diabetic foot ulcers.
    Turhan V; Mutluoglu M; Acar A; Hatipoğlu M; Önem Y; Uzun G; Ay H; Öncül O; Görenek L
    J Infect Dev Ctries; 2013 Oct; 7(10):707-12. PubMed ID: 24129622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimicrobial susceptibility of gram-negative and gram-positive bacteria collected from countries in Eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004-2010.
    Balode A; Punda-Polić V; Dowzicky MJ
    Int J Antimicrob Agents; 2013 Jun; 41(6):527-35. PubMed ID: 23590898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First point prevalence survey of nosocomial infections in the intensive care units of a tertiary care hospital in Albania.
    Faria S; Sodano L; Dauri M; Sabato AF; Gjata A; Kito I; Llazo E; Bilaj A; Mertiraj O; Schinaia N;
    J Hosp Infect; 2008 May; 69(1):95-7. PubMed ID: 18346815
    [No Abstract]   [Full Text] [Related]  

  • 31. How to stratify patients at risk for resistant bugs in skin and soft tissue infections?
    Guillamet CV; Kollef MH
    Curr Opin Infect Dis; 2016 Apr; 29(2):116-23. PubMed ID: 26779773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidemiology and microbiology of skin and soft tissue infections.
    Esposito S; Noviello S; Leone S
    Curr Opin Infect Dis; 2016 Apr; 29(2):109-15. PubMed ID: 26779772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
    Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
    J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.
    Morgan A; Cofer C; Stevens DL
    Future Microbiol; 2009 Mar; 4(2):131-44. PubMed ID: 19257839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microbiology of acute bacterial skin and skin-structure infections in Greece: A proposed clinical prediction score for the causative pathogen.
    Nodaras C; Kotsaki A; Tziolos N; Kontopoulou T; Akinosoglou K; Chrisanthakopoulou M; Kranidioti E; Kritselis I; Voloudakis N; Vittoros V; Gogkou A; Fillas I; Toutouzas KG; Bristianou M; Tsoutsos D; Christaki E; Adamis G; Kaziani K; Tsironis C; Lada M; Kokkinakis E; Sympardi S; Koutelidakis IM; Karkamanis A; Pantazi A; Bayram C; Alexiou Z; Mousoulis G; Gogos C; O'Hare M; Griffiths D; MacGowan A; Sambatakou H; Giamarellos-Bourboulis EJ
    Int J Antimicrob Agents; 2019 Dec; 54(6):750-756. PubMed ID: 31479742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Skin and soft tissue infection: microbiology and epidemiology.
    Dryden MS
    Int J Antimicrob Agents; 2009 Jul; 34 Suppl 1():S2-7. PubMed ID: 19560670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Shifting trends in bacterial keratitis in Toronto: an 11-year review.
    Lichtinger A; Yeung SN; Kim P; Amiran MD; Iovieno A; Elbaz U; Ku JY; Wolff R; Rootman DS; Slomovic AR
    Ophthalmology; 2012 Sep; 119(9):1785-90. PubMed ID: 22627118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.
    Jones RN; Ross JE; Bell JM; Utsuki U; Fumiaki I; Kobayashi I; Turnidge JD
    Diagn Microbiol Infect Dis; 2009 Dec; 65(4):404-13. PubMed ID: 19913683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antimicrobial activity and spectrum of cefovecin, a new extended- spectrum cephalosporin, against pathogens collected from dogs and cats in Europe and North America.
    Stegemann MR; Passmore CA; Sherington J; Lindeman CJ; Papp G; Weigel DJ; Skogerboe TL
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2286-92. PubMed ID: 16801403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.